Pharmaceutical Technology1 个月
RP-2 by Replimune for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
RP-2 is under clinical development by Replimune and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction ...